Literature DB >> 15748868

Regional expression of constitutive and inducible transcription factors following transient focal ischemia in the neonatal rat: influence of hypothermia.

Nina G Pabello1, Seth J Tracy, Abigail Snyder-Keller, Richard W Keller.   

Abstract

Ischemia is a potent modulator of gene expression. Differential expression of transcription factors after focal ischemia may reflect the potential for neuronal recovery in peri-ischemic regions. Previously, we demonstrated that hypothermia reduces the volume of damage in a model of neonatal focal ischemia. In the present study, immunocytochemistry was used to assess the temporal and spatial profiles of the transcription factors Fos and pCREB under normal and hypothermic conditions in this neonatal model of focal ischemia. At 7 days of age, rat pups underwent a permanent middle cerebral artery occlusion (MCAo) coupled with a temporary 1-h occlusion of the common carotid artery (CCAo). They were maintained at 37 degrees C throughout ischemia and reperfusion (Normothermic), or given 1 h of hypothermic conditions (28 degrees C) either during the occlusion (Intraischemic Hypothermia) or during the second hour of reperfusion (postischemic hypothermia). In normothermic pups, Fos immunoreactivity peaked at early time points (4-8 h post-ischemia) in a narrow band in peri-ischemic regions. By later stages of reperfusion (12-24 h), there was a more widespread induction in peri-ischemic regions including the ipsilateral cortex. In contrast with Fos, the constitutive transcription factor pCREB was reduced in core regions at all time points examined. Both the c-fos induction in peri-ischemic regions and the reduction of pCREB in the core were attenuated by intraischemic hypothermia. Postischemic hypothermia altered the distribution of Fos immunoreactivity without significantly changing the number of Fos- and pCREB-immunoreactive cells compared to normothermic rats. Both intra- and postischemic hypothermia reduced the number of caspase-immunoreactive cells. Thus, focal ischemia in the P7 rat produces different distributions of Fos and pCREB than what has been observed in adult rats subjected to focal ischemia, and expression of these transcription factors can be altered by hypothermia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15748868     DOI: 10.1016/j.brainres.2004.12.047

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.

Authors:  Tyisha Hathorn; Abigail Snyder-Keller; Anne Messer
Journal:  Neurobiol Dis       Date:  2010-08-22       Impact factor: 5.996

2.  Salvianolate lyophilized injection promotes post-stroke functional recovery via the activation of VEGF and BDNF-TrkB-CREB signaling pathway.

Authors:  Qiansong He; Shaoxia Wang; Xiaolei Liu; Hong Guo; Hongyun Yang; Li Zhang; Pengwei Zhuang; Yanjun Zhang; Zhengliang Ye; Limin Hu
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 3.  Bench-to-bedside review: Hypothermia in traumatic brain injury.

Authors:  H Louise Sinclair; Peter Jd Andrews
Journal:  Crit Care       Date:  2010-02-15       Impact factor: 9.097

Review 4.  Protection in animal models of brain and spinal cord injury with mild to moderate hypothermia.

Authors:  W Dalton Dietrich; Coleen M Atkins; Helen M Bramlett
Journal:  J Neurotrauma       Date:  2009-03       Impact factor: 5.269

5.  δ-Opioid receptor activation rescues the functional TrkB receptor and protects the brain from ischemia-reperfusion injury in the rat.

Authors:  Xuesong Tian; Jingchun Guo; Min Zhu; Minwei Li; Gencheng Wu; Ying Xia
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

6.  Molecular and cellular pathways as a target of therapeutic hypothermia: pharmacological aspect.

Authors:  Hyung Soo Han; Jaechan Park; Jong-Heon Kim; Kyoungho Suk
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.